Literature DB >> 16131580

Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study.

J W A Smit1, C F A Eustatia-Rutten, E P M Corssmit, A M Pereira, M Frölich, G B Bleeker, E R Holman, E E van der Wall, J A Romijn, J J Bax.   

Abstract

BACKGROUND: Subclinical hyperthyroidism has been reported to affect systolic and diastolic cardiac function. However, the reversibility of these effects is not well established.
OBJECTIVE: Our objective was to investigate the presence and reversibility of cardiac abnormalities in patients with long-term exogenous subclinical hyperthyroidism.
DESIGN: We conducted a prospective, single-blinded, placebo-controlled randomized trial of 6 months duration with two parallel groups.
SETTING: The study occurred at the Leiden University Medical Center, a tertiary referral center for thyroid carcinoma. PATIENTS: As a model for subclinical hyperthyroidism, 25 patients with a history of differentiated thyroid carcinoma with more than 10 yr of TSH suppressive therapy with L-T4 were studied.
INTERVENTIONS: L-T4 dose was replaced by study medication containing L-T4 or placebo. Medication was titrated in a single-blinded fashion to establish continuation of TSH suppression (low-TSH group) or euthyroidism (euthyroid group). MEASUREMENTS: We assessed serum levels of free T4 and TSH and used echo Doppler cardiography including tissue Doppler to establish left ventricular (LV) dimensions and function as well as diastolic function. Baseline echocardiography data were compared with 24 controls.
RESULTS: There were no differences in baseline cardiac parameters and TSH levels between the two groups. Although mean LV mass index was increased as compared with 24 controls, only four patients had LV hypertrophy at baseline. This was not improved by restoration of euthyroidism. At baseline, diastolic function was impaired in all patients as indicated by abnormal values for the peak flow of the early filling phase (E, 55.3 +/- 9.5 mm/sec), the ratio of E and the peak flow of the atrial filling phase (E/A ratio, 0.87 +/- 0.13), the early diastolic velocity obtained by tissue Doppler (E', 5.7 +/- 1.3 cm/sec), and the peak atrial filling velocity obtained by tissue Doppler (A', 6.8 +/- 1.4 cm/sec), prolonged E deceleration time (234 +/- 34 msec), and isovolumetric relaxation time (121 +/- 15 msec). After 6 months, significant improvements were observed in the euthyroid group in the E/A ratio (+41%; P < 0.001), E deceleration time (-18%; P = 0.006), isovolumetric relaxation time (-25%; P < 0.001), E' (+31%; P < 0.001), and the E'/A' ratio (+40%; P < 0.001).
CONCLUSIONS: We conclude that prolonged subclinical hyperthyroidism is accompanied by diastolic dysfunction that is at least partly reversible after restoration of euthyroidism. Because isolated diastolic dysfunction may be associated with increased mortality, this finding is of clinical significance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131580     DOI: 10.1210/jc.2005-0620

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Intra-left ventricular systolic asynchrony in patients with overt hyperthyroidism.

Authors:  Abdulkadir Kırış; Cihangir Erem; Gülhanım Kırış; Mustafa Koçak; Omer Gedikli; Irfan Nuhoğlu; Merih Kutlu; Tuba Kaplan; Mustafa Gökçe; Sükrü Celik
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  The metabolic consequences of thyroxine replacement in adult hypopituitary patients.

Authors:  Helena Filipsson Nyström; Ulla Feldt-Rasmussen; Ione Kourides; Vera Popovic; Maria Koltowska-Häggström; Björn Jonsson; Gudmundur Johannsson
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 3.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

Review 4.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

5.  Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.

Authors:  Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-13       Impact factor: 9.236

6.  Thyroid Function and Dysfunction in Relation to 16 Cardiovascular Diseases.

Authors:  Susanna C Larsson; Elias Allara; Amy M Mason; Karl Michaëlsson; Stephen Burgess
Journal:  Circ Genom Precis Med       Date:  2019-03

7.  P wave duration and dispersion in patients with hyperthyroidism and the short-term effects of antithyroid treatment.

Authors:  Unal Guntekin; Yilmaz Gunes; Hakki Simsek; Mustafa Tuncer; Sevket Arslan
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01

8.  Thyroid hormone levels within reference range are associated with heart rate, cardiac structure, and function in middle-aged men and women.

Authors:  Greet L Roef; Youri E Taes; Jean-Marc Kaufman; Caroline M Van Daele; Marc L De Buyzere; Thierry C Gillebert; Ernst R Rietzschel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

Review 9.  Thyroid cancer: possible role of telemedicine.

Authors:  G Gibelli; B Gibelli; F Nani
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-12       Impact factor: 2.124

10.  Changes in cardiac function and structure in newly diagnosed Graves' disease. A conventional and 2D-speckle tracking echocardiography study.

Authors:  K Aroditis; M Pikilidou; E Vourvouri; L Hadjistavri; P Zebekakis; J Yovos; G Efthimiadis; H Karvounis
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-28       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.